local_hospital

Facharzt für Psychiatrie und Psychotherapie

Address
Olof-Palme-Platz 4, 18439 Stralsund, Germany

Adjunctive Treatment for Major Depressive Disorder

The site evaluates additional therapies to standard antidepressants for adults with Major Depressive Disorder.

  • Milsaperidone as an adjunctive agent
  • SEP-363856 flexible dosing regimen
  • Efficacy measured by change in MADRS score
  • Safety and tolerability assessments

These studies aim to improve outcomes for patients who have an inadequate response to conventional antidepressant therapy, advancing treatment options in Stralsund, Germany.

Psychiatric Research in Nervous System Disorders

Research at the Facharzt für Psychiatrie und Psychotherapie targets mental disorders within the broader field of nervous system diseases.

  • Adjunctive strategies for depression
  • Evaluation of novel pharmacologic compounds
  • Patient‑centered outcome measures
  • Collaboration with local clinicians and institutions

With a focused program of two trials led by a single investigator, the site contributes valuable data to the European mental health research community.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
8
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
2
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
2
Outperforms 47% of sites
public
Therapeutic diversity
2areas
Outperforms 62% of sites
groups
Sponsor diversity
2sponsors
Outperforms 51% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Facharzt für Psychiatrie und Psychotherapie

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2/3, Multicenter, Randomized, Double blind, Placebo controlled Trial of the Safety and Efficacy of Flexible Doses of SEP 363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.Otsuka Pharmaceutical Development & Commercialization Inc.Phase IVNot RecruitingMar 2023Nov 2025

IMP list

lock Showing 1 of 8 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
(1S)-1-[4-[3-[4-(6-FLUORO-1,2-BENZOXAZOL-3-YL)PIPERIDIN-1-YL]PROPOXY]-3-METHOXYPHENYL]ETHANOL1Unknown2025-09-262025-09-26

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.